Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496243 · ClinicalTrials.gov registry record · Phase 2
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
A Phase 2 study of Dyslipidemias, sponsored by NewAmsterdam Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT06496243: Recruiting Phase 2 study of Dyslipidemias, sponsored by NewAmsterdam Pharma.
NCT06496243 is a Phase 2 study of Dyslipidemias that is actively recruiting participants, run by NewAmsterdam Pharma. The registered enrollment target is 69 participants, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06496243, a Phase 2 study of Dyslipidemias, is actively recruiting participants, sponsored by NewAmsterdam Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Primary Outcome
Lp(a) change on combination therapy
Conditions Studied
Interventions
- DRUG obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Study Locations (1)
Pennsylvania
- UPenn - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What NCT06496243 shows while recruiting
NCT06496243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 1 intervention - of which obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks is the first listed.
NCT06496243 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06496243 about?
NCT06496243 is a clinical study titled "Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels". The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 T...
What is the current status of trial NCT06496243?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2024-12-02. Estimated completion is 2026-02.
What conditions does trial NCT06496243 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT06496243?
The interventions under investigation include: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks (DRUG).
Who is sponsoring clinical trial NCT06496243?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496243 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06496243's enrollment target sits among peer trials
69 20th of 28 higher than 9 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Causal Mechanisms in Adolescent Arterial Stiffness
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
COMPLETED · Phase 2
-
Study of ARO-APOC3 in Adults With Dyslipidemia
COMPLETED · Phase 2
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI